Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide

Prostate

Volumn 74, Issue 16, 2014, Pages 1691-1696

  Conteduca, Vincenza ^a   Burgio, Salvatore Luca ^a   Menna, Cecilia ^a   Carretta, Elisa ^a   Rossi, Lorena ^a   Bianchi, Emanuela ^a   Masini, Carla ^a   Amadori, Dino ^a   De Giorgi, Ugo ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

Author keywords

castration resistant prostate cancer; chromogranin A; enzalutamide; outcome; PSA

Indexed keywords

CHROMOGRANIN A; ENZALUTAMIDE; TUMOR MARKER; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; HUMAN; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RETROSPECTIVE STUDY; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHROMOGRANIN A; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84921956580     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22890     Document Type: Article

References (27)

1. Harris WP, Mostaghel EA, Nelson PS, Montgomery B,. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6: 76-85.
2. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12: 1665-1671.
3. Yuan X, Cai C, Chen S, Chen S, Yu Z, Balk SP,. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2014; 33: 22: 2815-2825.
4. Karantanos T, Corn PG, Thompson TC,. Prostate cancer progression after androgen deprivation therapy: Mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013; 32: 5501-5511.
5. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efastathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL,. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010; 375: 1437-1446.
6. Scher HI, Fizazi K, Saad F, Taplin ME, Sterberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS,. AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197.
7. Conteduca V, Aieta M, Amadori D, De Giorgi U,. Current evidence and emerging perspectives on neuroendocrine differentiation in prostate cancer. Crit Rev Oncol Hematol 2014; pii: S1040-8428(14)00087-0. doi: 10.1016/j.critrevonc.2014.05.008.
8. Beltran H, Tagawa ST, Park K, MacDonald TY, Milowsky MI, Mosquera JM, Rubin MA, Nanus DM,. Challenges in recognizing treatment related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386-e389.
9. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H,. Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009; 16: 37-44.
10. Hirano D, Okada Y, Minei S, Takimoto Y, Nemoto N,. Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy. Eur Urol 2004; 45: 586-592.
11. Sun Y, Niu J, Huang J,. Neuroendocrine differentiation in prostate cancer. Am J Transl Res 2009; 1: 148-162.
12. Berruti A, Mosca A, Tucci M, Terrone C, Torta M, Tarabuzzi R, Russo L, Cracco C, Bollito E, Scarpa RM, Angeli A, Dogliotti L,. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. Endocr Relat Cancer 2005; 12: 109-117.
13. Sciarra A, Di Silverio F, Autran AM, Salciccia S, Gentilucci A, Alfarone A, Gentile V,. Distribution of high chromogranin A serum levels in patients with nonmetastatic and metastatic prostate adenocarcinoma. Urol Int 2009; 82: 147-151.
14. Matei DV, Renne G, Pimentel M, Sandri MT, Zorzino L, Botteri E, De Cicco C, Musi G, Brescia A, Mazzoleni F, Tringali V, Detti S, de Cobelli O,. Neuroendocrine differentiation in castration-resistant prostate cancer: A systematic diagnostic attempt. Clin Genitourin Cancer 2012; 10: 164-173.
15. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005.
16. Burgio SL, Conteduca V, Menna C, Carretta E, Rossi L, Bianchi E, Kopf B, Fabbri F, Amadori D, De Giorgi U,. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone. Endocr Relat Cancer 2014; 21 (3): 487-493.
17. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW,. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in cancer and leukemia Group B 9480 study. Urology 2005; 66: 386-391.
18. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M,. Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159.
19. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Mjølnerød OK, Waldum HL,. Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings ? Prostate 1997; 30: 1-6.
20. Noordzij MA, van der Kwast TH, van Steenbrugge GJ, Hop WJ, Schroder FH,. The prognostic influence of neuroendocrine cells in prostate cancer: Results of a long-term follow-up study with patients treated by radical prostatectomy. Int J Cancer 1995; 62: 252-258.
21. Abrahamsson PA, Cockett ATK, Di Sant'Agnese PA,. Prognostic significance of neuroendocrine differentiation in clinical localized prostatic carcinoma. Prostate Suppl 1998; 8: 37-42.
22. Ahlegren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson P,. Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume. Urology 2000; 56: 1011-1015.
23. Lilleby W, Paus E, Skovlund E, Fossa SD,. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001; 46: 126-133.
24. Foster BA, Gangavarapu Kj, Mathew G, Azabdaftari G, Morrison CD, Miller A, Huss WJ,. Human prostate side population cells demonstrate stem cell properties in recombination with urogenital sinus mesenchyme. PLoS ONE 2013; 8: e55062.
25. Vander Griend DJ, Karthaus WL, Dalrymple S, Meeker A, DeMarzo AM, Isaacs JT,. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008; 68: 9703-9711.
26. Germann M, Wetterwald A, Guzmán-Ramirez N, van der Pluijm G, Culig Z, Cecchini MG, Williams ED, Thalmann GN,. Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer. Stem Cells 2012; 30: 1076-1086.
27. Bae KM, Su Z, Frye C, McClellan S, Allan RW, Andrejewski JT, Kelley V, Jorgensen M, Steindler DA, Vieweg J, Siemann DW,. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. J Urol 2010; 183: 2045-2053.